Sputtr.com | Alternative Search Engine

Aventis

Sanofi-aventis to Acquire Genzyme

Sanofi-aventis Genzyme Media Contact : Media Contact : Jean-Marc Podvin Bo Piela +33 1 53 77 44 50 617-768-6579 508-308-9783 Investor Contact : Investor Contact : Sébastien Martel Patrick Flanigan +33 1 53 77 45 45 617-768-6563 617-816-9521 CONFERENCE CALL Sanofi-aventis and Genzyme will host ...

WARNINGS AND PRECAUTIONS —————————————

www.sanofi-aventis.us or call sanofi-aventis Medical Information Services at 1-800-633-1610 option 1. The Medication Guide may have changed since this copy was printed. 6.

HIGHLIGHTS OF PRESCRIBING INFORMATION

sanofi-aventis Subject: Xyzal Prescribing Information Keywords: Xyzal (levocetirizine dihydochloride) Prescribing Information Created Date: 1/27/2011 12:11:04 PM ...

Amaryl (glimepiride) Leaflet

Manufactured by: Aventis Pharma S.p.A., Scoppito, Italy. Repacked by: sanofi-aventis Pakistan limited. Plot No. 23, Sector 22, Korangi Industrial Area, Karachi. 514313-01.

Information about the sanofi-aventis U.S. Patient Assistance ...

Information about the sanofi-aventis U.S. Patient Assistance Foundation Program • Once you qualify, you may be able to receive free medication for up to 12 months.

Aprovel (irbesartan) - 150mg - Film-coated tablets

PLEASE READ ALLOFTHE LEAFLET CAREFULLY BEFORE TAKING THIS MEDICINE. - Keep this leaflet you may need to read it again. - Ifyou have any other questions or doubts, ask your doctor or pharmacist for further information.

sanofi-aventis U.S. Patient Assistance Program P.O. Box 759 ...

sanofi-aventis_PDP_Appeal TA.doc sanofi-aventis U.S. Patient Assistance Program P.O. Box 759, Somerville, NJ 08876 Phone: (800) 221-4025 Fax: (866) 734-7372 MEDICARE PART D PRESCRIPTION DRUG PLAN APPEAL FOR MEDICINES NEEDED FOR LIFE THREATENING CONDITIONS This is an appeal from a _____ ( DATE ...

Sanofi-Aventis Completes Acquisition of Genzyme Corporation

Sanofi-aventis www.sanofi-aventis.com Media Relations: Tel. : (+) 33 1 53 77 44 50 - E-mail : MR@sanofi-aventis.com Investor Relations : Tel. : (+) 33 1 53 77 45 45 - E-mail : IR@sanofi-aventis.com

S UMMARY OF PRODUCT CHARACTERISTICS

7 M ARKETI NG AUTHORISATION HOLDER Sanofi - aventis One Onslow Street Guildford Surrey GU1 4YS 8 M ARKETING AUTHORISATION NUMBER(S) 200 mg: PL 04425 ...

Warning Letter: Sanofi-Aventis

DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Rockville MD 20857 WARNING LETTER VIA EMAIL AND CERTIFIED MAIL RETURN RECEIPT REQUESTED Gregory Irace Chief Executive Officer Sanofi-Aventis U.S. LLC. 55 Corporate Drive Bridgewater, NJ 08807 Ref: 07-HFD-45-1002 Dear Mr. Irace ...